Ownership and insider activity for Jaguar Health, Inc. (JAGX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health.
Price
| Price | $0.23 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-12-11 | MICEK JOHN | A-Award | 7,377 | |
| 2025-12-11 | MICEK JOHN | A-Award | 7,377 | $11K |
| 2025-12-11 | King Steven R. | A-Award | 11,740 | |
| 2025-12-11 | King Steven R. | A-Award | 11,740 | $17K |
| 2025-12-11 | CONTE LISA A | A-Award | 28,592 | |
| 2025-12-11 | CONTE LISA A | A-Award | 28,592 | $41K |
| 2025-12-11 | Wolin Jonathan S. | A-Award | 11,740 | |
| 2025-12-11 | Wolin Jonathan S. | A-Award | 11,740 | $17K |
| 2025-12-11 | Chaturvedi Pravin R | A-Award | 11,740 | |
| 2025-12-11 | Chaturvedi Pravin R | A-Award | 11,740 | $17K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $950979 | $520698 | $2.6M | $3.5M | $8.1M | $17.1M | $5.5M | $6.5M | $8.0M | $968000 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $304611 | $469038 | $1.0M | $1.7M | $4.6M | $2.1M | $2.5M | $2.2M | $1.6M | $1.7M |
| Inventory | $412754 | $2.1M | $3.3M | $2.1M | $2.8M | $4.9M | $7.0M | $9.2M | $10.3M | $8.6M |
| Total Current Assets | $2.6M | $3.8M | $8.1M | $9.5M | $17.8M | $28.4M | $22.3M | $28.0M | $32.2M | $20.3M |
| Property, Plant & Equipment | $885945 | $1.2M | $760617 | $710000 | $677000 | $1.7M | $1.7M | $1.7M | $1.4M | $1.5M |
| Goodwill | 0 | $5.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | $33.4M | $31.7M | $26.0M | $24.3M | $22.7M | $22.4M | $20.1M | $18.5M | $16.0M |
| Total Assets | $3.6M | $43.6M | $41.0M | $36.4M | $42.8M | $53.3M | $47.5M | $50.8M | $53.4M | $38.3M |
| Accounts Payable | $517000 | $7.4M | $5.4M | $5.4M | $4.8M | $4.9M | $5.8M | $5.0M | $5.3M | $8.7M |
| Short-term Debt | $2.1M | $5.4M | $16.1M | $6.8M | $3.8M | $3.2M | $15.9M | $4.9M | $12.0M | $27.4M |
| Total Current Liabilities | $4.2M | $15.4M | $26.7M | $15.4M | $13.2M | $15.5M | $30.3M | $14.0M | $19.7M | $40.7M |
| Long-term Debt | $1.8M | $11.0M | 0 | $450000 | $12.4M | $25.0M | $17.7M | $31.0M | $23.5M | $15.1M |
| Total Liabilities | $6.0M | $26.4M | $35.7M | $25.7M | $25.6M | $41.4M | $48.8M | $45.9M | $46.9M | $57.0M |
| Retained Earnings | -$40.4M | -$62.4M | -$94.6M | -$133.1M | -$166.9M | -$219.5M | -$266.9M | -$308.2M | -$346.5M | -$399.9M |
| Total Equity | -$2.5M | $17.3M | $5.4M | $10.7M | $17.2M | $11.6M | -$657000 | $5.0M | $7.3M | -$17.3M |
| Total Debt | $3.9M | $16.4M | $16.1M | $7.6M | $16.2M | $29.4M | $34.8M | $37.1M | $36.5M | $43.6M |
| Net Debt | $2.9M | $15.9M | $13.5M | $4.1M | $8.1M | $12.3M | $29.4M | $30.6M | $28.5M | $42.6M |
| Working Capital | -$1.6M | -$11.6M | -$18.5M | -$5.9M | $4.6M | $13.0M | -$8.0M | $14.0M | $12.5M | -$20.3M |
Financial Health
| Debt / Equity | 2.52 |
| Current Ratio | 0.69 |
Profitability
| Return on Equity | 762.51% |
| Return on Invested Capital | -109.75% |
| Return on Assets | -107.18% |
| Gross Margin | 82.31% |
| Operating Margin | -90.22% |
| Net Margin | -131.76% |
Related companies: BDRX · CANF · CLDI · CNSP · GNPX · GRI · INM
Explore sector: Healthcare · Biotechnology
More sections of JAGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks